Download Full Text (1.5 MB)
College, Institute, or Department
Pathology and Microbiology
Dr. Rakesh K. Singh
Pancreatic ductal adenocarcinoma (PDAC) has one of the lowest survival rates of all cancers in the United States. Not only is PDAC found at the late stages, but patients also present with or develop chemotherapy resistance at an elevated frequency. Left with limited options for treatment, researchers are investigating new options for these patients. One major area of interest is the sub-population of cells in the tumor called cancer stem cells (CSCs). These cells are known for having high resistance to chemotherapy, along with propagating and re-building the tumor after most non-CSCs have been therapeutically targeted. Previous studies have determined CXCR4, ALDH1, CD24, CD44, and CD133 as markers for CSC-like PDAC cells. In the present study, we investigate the closely related CXCR1 as another possible marker and therapeutic target for PDAC CSCs. CXCR1 is known for its role in inflammation and wound healing. The CXCR1 axis includes the ligands CXCL6 and IL-8, both of which promote the progression of cancer. Previously, Ginesteir et al. has shown targeting the CXCR1 axis in triple negative breast cancer reduced CSC-like phenotypes in vitro and in vivo. Investigations of CXCR1 in PDAC demonstrate IL-8 induces increased tumorsphere formation in vitro (Chen et al.), leading us to investigating CXCR1 in PDAC CSCs. We hypothesize that PDAC cells with high CXCR1 activity also exhibit increased CSC-like characteristics and targeting CXCR1 will reduce those characteristics.
To investigate the role of CXCR1 in CSC-like phenotype of PDAC, we used the PDAC cell line CD18, along with its gemcitabine resistant (GemR) counterpart. We used the CXCR1/2 antagonist Navarixin at high enough concentrations to inhibit CXCR1. Using the previously found gemcitabine and navarixin IC50 concentrations for each parent cell line, we treated cells for 72 hours. Post-treatment, we analyzed the expression of several known CSC markers, CXCR1, and IL-8 through qRT-PCR and ELISA. We expected to see higher expression and activity of CXCR1 in cells with higher known CSC marker expression. We also anticipated that gemcitabine treatment would induce higher expression of CSC markers, whereas navarixin would exhibit lower expression. From our results, we see the beginning trends of gemcitabine treated cells having increased expression of the CSC markers and navarixin decreasing or not changing the expression levels. These results differ for IL-8, which undergoes an increase in expression when treated with both gemcitabine and navarixin, which may warrant further exploration into the role of ligands in CSC-like phenotypes. One possible explanation for this difference would be the regulation of IL-8 expression based on CXCR1 activity, as IL-8 interacts with CXCR1.
Cancer Stem Cells, CSC, Pancreatic Ductal Adenocarcinoma, CXCR1, Chemotherapy Resistance
Thomas, Elizabeth; Molczyk, Caitlin; Goel, Paran; Powers, Marie; Zaman, Lubaba A.; Ehrhorn, Evie; Cohen, Samuel; and Singh, Rakesh K., "The CXCR1 Axis: A Putative Therapeutic Cancer Stem Cell-Like Marker in Pancreatic Ductal Adenocarcinoma" (2021). Posters: 2021 Summer Undergraduate Research Program. 36.